Latest ArticlesEN-USFri, 24 Jun 2016 23:20:22 -0400639890
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K6AtvManYWs/as-cost-panel-gets-delayed-buy-these-3-biotech-etfs-cm639890
As Cost Panel Gets Delayed, Buy These 3 Biotech ETFsBiotechnology stocks climbed up yesterday and today on news that a cost cutting body from Obamacare, known as the Independent Payment Advisory Board (IPAB), is expected to be enacted in 2017. While this means that biotech companies will have<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/K6AtvManYWs" height="1" width="1" alt=""/>Thu, 23 Jun 2016 22:58:46 Z2016-06-23T22:58:46Zhttp://www.nasdaq.com/article/as-cost-panel-gets-delayed-buy-these-3-biotech-etfs-cm639890638509
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O90-X6Dmehc/juno-crosses-below-key-moving-average-level-cm638509
JUNO Crosses Below Key Moving Average LevelIn trading on Tuesday, shares of Juno Therapeutics Inc (Symbol JUNO) crossed below their 200 day moving average of $41.95, changing hands as low as $41.82 per share. Juno Therapeutics Inc shares are currently trading down about 2.7% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/O90-X6Dmehc" height="1" width="1" alt=""/>Tue, 21 Jun 2016 16:57:03 Z2016-06-21T16:57:03Zhttp://www.nasdaq.com/article/juno-crosses-below-key-moving-average-level-cm638509636536
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OUn1Z9nDlfo/qiagen-enters-oversold-territory-qgen-cm636536
Qiagen Enters Oversold Territory (QGEN)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/OUn1Z9nDlfo" height="1" width="1" alt=""/>Thu, 16 Jun 2016 18:06:47 Z2016-06-16T18:06:47Zhttp://www.nasdaq.com/article/qiagen-enters-oversold-territory-qgen-cm636536635352
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MWTVJxwjY-Y/neurocrine-biosciences-breaks-below-200-day-moving-average-notable-for-nbix-cm635352
Neurocrine Biosciences Breaks Below 200-Day Moving Average - Notable for NBIXIn trading on Tuesday, shares of Neurocrine Biosciences, Inc. (Symbol NBIX) crossed below their 200 day moving average of $45.94, changing hands as low as $45.72 per share. Neurocrine Biosciences, Inc. shares are currently trading off about 1.2% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/MWTVJxwjY-Y" height="1" width="1" alt=""/>Tue, 14 Jun 2016 18:09:25 Z2016-06-14T18:09:25Zhttp://www.nasdaq.com/article/neurocrine-biosciences-breaks-below-200-day-moving-average-notable-for-nbix-cm635352634342
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aq8cqW7whwM/fbts-underlying-holdings-could-mean-28-gain-potential-cm634342
FBT's Underlying Holdings Could Mean 28% Gain PotentialLooking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/aq8cqW7whwM" height="1" width="1" alt=""/>Mon, 13 Jun 2016 12:19:50 Z2016-06-13T12:19:50Zhttp://www.nasdaq.com/article/fbts-underlying-holdings-could-mean-28-gain-potential-cm634342634049
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mKZvvghhGn4/oversold-conditions-for-myriad-genetics-mygn-cm634049
Oversold Conditions For Myriad Genetics (MYGN)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/mKZvvghhGn4" height="1" width="1" alt=""/>Fri, 10 Jun 2016 22:13:24 Z2016-06-10T22:13:24Zhttp://www.nasdaq.com/article/oversold-conditions-for-myriad-genetics-mygn-cm634049631769
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H4QhaAhJWds/relative-strength-alert-for-ionis-pharmaceuticals-cm631769
Relative Strength Alert For Ionis PharmaceuticalsLegendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/H4QhaAhJWds" height="1" width="1" alt=""/>Tue, 07 Jun 2016 18:11:01 Z2016-06-07T18:11:01Zhttp://www.nasdaq.com/article/relative-strength-alert-for-ionis-pharmaceuticals-cm631769629692
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YefzY0F1UHc/agio-crosses-above-key-moving-average-level-cm629692
AGIO Crosses Above Key Moving Average LevelIn trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol AGIO) crossed above their 200 day moving average of $58.79, changing hands as high as $60.20 per share. Agios Pharmaceuticals Inc shares are currently trading up about 3.6% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/YefzY0F1UHc" height="1" width="1" alt=""/>Thu, 02 Jun 2016 17:55:20 Z2016-06-02T17:55:20Zhttp://www.nasdaq.com/article/agio-crosses-above-key-moving-average-level-cm629692629062
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L6dySAZmGIw/icpt-makes-bullish-cross-above-critical-moving-average-cm629062
ICPT Makes Bullish Cross Above Critical Moving AverageIn trading on Wednesday, shares of Intercept Pharmaceuticals Inc (Symbol ICPT) crossed above their 200 day moving average of $152.18, changing hands as high as $152.40 per share. Intercept Pharmaceuticals Inc shares are currently trading up about 2.4% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/L6dySAZmGIw" height="1" width="1" alt=""/>Wed, 01 Jun 2016 17:05:15 Z2016-06-01T17:05:15Zhttp://www.nasdaq.com/article/icpt-makes-bullish-cross-above-critical-moving-average-cm629062627116
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dj-K-UfGspU/thursdays-etf-movers-xlu-fbt-cm627116
Thursday's ETF Movers: XLU, FBTIn trading on Thursday, the Utilities Select Sector SPDR Fund ETF ( XLU ) is outperforming other ETFs, up about 0.9% on the day. Components of that ETF showing particular strength include shares of Ameren ( AEE ), up<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Dj-K-UfGspU" height="1" width="1" alt=""/>Thu, 26 May 2016 19:04:40 Z2016-05-26T19:04:40Zhttp://www.nasdaq.com/article/thursdays-etf-movers-xlu-fbt-cm627116624390
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gv9u25De1nE/biotech-stocks-show-signs-of-revival-but-beware-of-side-effects-cm624390
Biotech Stocks Show Signs Of Revival, But Beware Of Side EffectsAfter being one of the worst performing sectors since last summer, biotechnology firms have shown a few encouraging signs since March. ETF flow into the sector was a positive $480 million in March, according to Mizuho<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gv9u25De1nE" height="1" width="1" alt=""/>Fri, 20 May 2016 21:47:31 Z2016-05-20T21:47:31Zhttp://www.nasdaq.com/article/biotech-stocks-show-signs-of-revival-but-beware-of-side-effects-cm624390623613
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nqgk95jKZvg/seattle-genetics-breaks-above-200-day-moving-average-bullish-for-sgen-cm623613
Seattle Genetics Breaks Above 200-Day Moving Average - Bullish for SGENIn trading on Thursday, shares of Seattle Genetics Inc (Symbol SGEN) crossed above their 200 day moving average of $38.69, changing hands as high as $38.92 per share. Seattle Genetics Inc shares are currently trading off about 0.3% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Nqgk95jKZvg" height="1" width="1" alt=""/>Thu, 19 May 2016 17:47:31 Z2016-05-19T17:47:31Zhttp://www.nasdaq.com/article/seattle-genetics-breaks-above-200-day-moving-average-bullish-for-sgen-cm623613622263
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n1w3Iy9qUVE/bullish-two-hundred-day-moving-average-cross-acad-cm622263
Bullish Two Hundred Day Moving Average Cross - ACADIn trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol ACAD) crossed above their 200 day moving average of $31.56, changing hands as high as $32.20 per share. Acadia Pharmaceuticals Inc shares are currently trading up about 7.1% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/n1w3Iy9qUVE" height="1" width="1" alt=""/>Tue, 17 May 2016 16:49:08 Z2016-05-17T16:49:08Zhttp://www.nasdaq.com/article/bullish-two-hundred-day-moving-average-cross-acad-cm622263621667
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PghyUhAFoqg/neurocrine-biosciences-breaks-above-200-day-moving-average-bullish-for-nbix-cm621667
Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIXIn trading on Monday, shares of Neurocrine Biosciences, Inc. (Symbol NBIX) crossed above their 200 day moving average of $45.90, changing hands as high as $46.07 per share. Neurocrine Biosciences, Inc. shares are currently trading up about 5.1% on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/PghyUhAFoqg" height="1" width="1" alt=""/>Mon, 16 May 2016 17:48:14 Z2016-05-16T17:48:14Zhttp://www.nasdaq.com/article/neurocrine-biosciences-breaks-above-200-day-moving-average-bullish-for-nbix-cm621667621044
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TTAXQNuy0lw/what-lies-ahead-for-biotech-etfs-cm621044
What Lies Ahead for Biotech ETFs?The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining 17.5% year to date. Compare this to the spectacular performance over the last few years and one wonders whether the dream run<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/TTAXQNuy0lw" height="1" width="1" alt=""/>Fri, 13 May 2016 22:47:39 Z2016-05-13T22:47:39Zhttp://www.nasdaq.com/article/what-lies-ahead-for-biotech-etfs-cm621044